Age-standardized mortality from ischaemic heart disease in European regions (men; age group 45-74 years; year 2000) J Muller-Nordhorn, et al. Eur Heart.

Slides:

Advertisements

Similar presentations

Statins for ischaemic heart disease: Excellence and equity Hackney, Newham & Tower Hamlets.

Advertisements

Mortality by country of birth in England and Wales, Clare Griffiths & Anita Brock: Office for National Statistics Sarah Wild & Colin Fischbacher:

Key messages Stephen S Lim, et al. Lancet 2007; 370:

PAD A Call to Action. PAD: A Call to Action - What is peripheral arterial disease (PAD)? and why is it so dangerous? - Diagnosing PAD in the primary care.

Hazard of incident coronary heart disease by diabetes status, with or without elevation of troponin T No diabetes Pre- diabetes Diabetes No diabetes Pre-

Cardiovascular mortality in Russia and other countries

The relationship between body mass index, treatment, and mortality in patients with established coronary artery disease: a report from APPROACH by Antigone.

Canadian Cardiovascular Outcomes Research Team A Canadian Institutes of Health Research - Heart and Stroke Foundation of Canada Interdisciplinary.

Competing causes of death European Society of Cardiology Congress Paris, August 28, 2011 Ulrich Keil and Angela Spelsberg Institute of Epidemiology and.

Kotseva K, et al. Eur J Cardiovasc Prev Rehabil 2009 Mar 12 [Epub]

Zacho J, et al. N Engl J Med 2008;359: Risk of Ischemic Heart Disease as a Function of Plasma Levels of C-Reactive Protein (CRP) in the General.

Consider testing if person is: – Overweight or obese with additional risk factor for diabetes – Age 45 or older Obtain: A1C or FPG or 2-hour plasma glucose.

Impact of Socioeconomic Status on Cardiovascular Disease and Mortality in 24,947 Individuals With Type 1 Diabetes Featured Article: Araz Rawshani, Ann-Marie.

Berlin Mare Ainsaar. Population influences everything Values Housing Media use Transportation Services Criminality Innovation Natural recources.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

How can you estimate simply the cardiovascular risk of your patients?

Central blood pressure: what do we really know today?

The combined influence of leisure-time physical activity and weekly alcohol intake on fatal ischaemic heart disease and all-cause mortality by Jane Østergaard.

Primary care organisational interventions for secondary prevention of ischaemic heart disease: a systematic review and meta-analysis by Edel Murphy, Akke.

Parish S, et al. Eur Heart J 2009 [Epub ahead of print]

An update on regional variation in cardiovascular mortality within Europe by Jacqueline Müller-Nordhorn, Sylvia Binting, Stephanie Roll, and Stefan N.

To establish whether a difference in SBP between arms is associated with peripheral or cardiovascular (CV) disease, and with an increased risk of CV or.

Length of life and the pensions of five million retired German men by Vladimir M. Shkolnikov, Rembrandt Scholz, Dmitri A. Jdanov, Michael Stegmann, and.

Source: WHO Global Burden of Disease Report Update 2004, Geneva 2008 Global Burden of Disease: chronic NCD responsible for high rates of premature mortality.

Process of study selection F. Sofi, et al. BMJ 2008 Sep 11;337:a1344.

Mortality trends in cardiovascular causes in schizophrenia, bipolar and unipolar mood disorder in Sweden 1987–2010 by Urban Ösby, Jeanette Westman, Jonas.

Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension.

Unnecessary Lipid Screening of Inpatient Admissions Dennis Whang 4/2/12 DSR2.

Prognostic value of coronary artery calcium screening in asymptomatic smokers and non-smokers by Leslee J. Shaw, Paolo Raggi, Tracy Q. Callister, and Daniel.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

Presented by Slyter Nutrition Consulting Services.

High heart rate: a cardiovascular risk factor? by Stéphane Cook, Mario Togni, Marcus C. Schaub, Peter Wenaweser, and Otto M. Hess EHJ Volume 27(20):

Deﬁnitions of the MetS by the WHO, EGIR, NCEP, ACE, IDF, and updated NCEP criteria Wang J, et al. Eur Heart J 2007;28:

Fig. 1 Flow chart of study selection

Fatal and Nonfatal Cardiovascular Disease and the Use of Therapies for Secondary Prevention in a Rural Region of India by Rohina Joshi, Clara K. Chow,

Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.

Figure 1 Prevalence of functional mitral regurgitation according to NYHA functional class (A; P

Adapted with permission from Hsia, J et al

End point Patients >75 y with renal insufficiency

Figure 4 BMI and mortality in patients with heart failure

Proportion of Sudden Unexpected Death in North Carolina (SUDDEN) men and women with coronary artery disease (CAD) aged 56–64 years by source of medical.

VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =

Figure 4 Prevalence of HFpEF and HFrEF by age

Impact of risk factors and age of initiation of therapy on the distribution of lifespan gain. ‘National average risk’ refers to a cohort beginning at age.

Sudden Unexpected Death in North Carolina (SUDDEN) Gender and Ethnicity by Age—the majority of the cohort is over age 55 years, especially black men but.

Figure 1 Hazard ratios as a function of annual mean PM2

Classification of statins/dosages according to the attainable

Baseline Characteristics of Cardiovascular Risk Factors and Selected Dietary Variables in a Cohort of 22,881 Men and 35,091 Women to Quintile of Fish Intakes.

Baseline Characteristics by Tertiles of Homocysteine

Association between cardiovascular disease, cardiovascular risk factors and chronic obstructive pulmonary disease (COPD) on mortality. Association between.

Prevalence of comorbidities in pooled studies of patients with chronic obstructive pulmonary disease (COPD). Prevalence of comorbidities in pooled studies.

(A) 1-year mortality in relation to estimated glomerular filtration rate (eGFR), age (n=47 636) and presence of diabetes mellitus (n=47 624). (A) 1-year.

Age-specific mortality rates from CHD and stroke in women and men in 2010 in selected countries. Age-specific mortality rates from CHD and stroke in women.

Forest plots of randomised controlled trials and propensity score matched studies examining outcomes between patients taking proton pump inhibitor (PPIs)

A)Standardised mortality ratios for chronic bronchitis in men and women (1968–1978) and b) infant mortality from bronchitis and pneumonia per 1000 births.

Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.

UK paediatric cardiac surgery mortality rate by year for all cases and total number of procedures performed between 2000 and 2009/2010. UK paediatric cardiac.

Kaplan-Meier curve of cumulative percentage of cardiac mortality by peak flow rate category (adjusted HRs (95% CI) compared with ≥550 L/min: (

Flow chart of search strategy

Flow chart of the cohort selection for the study

Kaplan–Meier plots of 5 and 12-year all cause (A and C, respectively) and cardiovascular mortality (B and D, respectively) with number of participants.

Exercise confers cardioprotection through improved vascular function.

Kaplan-Meier survival curves for non-fatal stroke or mortality based on IMRS categories among (A) women (p-trend

Morbidity and mortality benefits with statin use in observational studies on a logarithmic scale. Morbidity and mortality benefits with statin use in observational.

Multivariable-adjusted HRs and 95% CIs for outcomes for waist circumference. Multivariable-adjusted HRs and 95% CIs for outcomes for waist circumference.

Kaplan-Meier survival curves of the IMRS association with non-fatal stroke/mortality (stroke-free survival) in women with AF, stratified by CHA2DS2-VASc.

Coloured dotplot of mortality rate per population in Scotland by age for those aged 30 to 89 years, from 1974 to 2015, stratified by sex for IHD.

Adjusted cumulative incidence of stroke, by sex and heart failure status. Adjusted cumulative incidence of stroke, by sex and heart failure status. The.

Comparison of investigator-reported and mortality adjudication committee-adjudicated fatal events (myocardial infarction, sudden death, sudden cardiac.

Adjusted cumulative disability incidence by sex and heart failure status. Adjusted cumulative disability incidence by sex and heart failure status. The.

Presentation transcript:

Age-standardized mortality from ischaemic heart disease in European regions (men; age group years; year 2000) J Muller-Nordhorn, et al. Eur Heart J 2008;29:Epub online

Age-standardized mortality from ischaemic heart disease in European regions (women; age group years; year 2000) J Muller-Nordhorn, et al. Eur Heart J 2008;29:Epub online

Age-standardized mortality from cerebrovascular disease in European regions (men; age group years; year 2000) J Muller-Nordhorn, et al. Eur Heart J 2008;29:Epub online

Age-standardized mortality from cerebrovascular disease in European regions (women; age group years; year 2000) J Muller-Nordhorn, et al. Eur Heart J 2008;29:Epub online

Age-standardized mortality from cardiovascular disease, i.e. ischaemic heart disease and cerebrovascular disease combined, in European regions (men; age group years; year 2000) J Muller-Nordhorn, et al. Eur Heart J 2008;29:Epub online

Age-standardized mortality from cardiovascular disease, i.e. ischaemic heart disease and cerebrovascular disease combined, in European regions (women; age group years; year 2000) J Muller-Nordhorn, et al. Eur Heart J 2008;29:Epub online

Age-standardized mortality rates (45–74 years) from ischaemic heart disease in Europe (2000) J Muller-Nordhorn, et al. Eur Heart J 2008;29:Epub online

Age-standardized mortality rates (45–74 years) from cerebrovascular disease in Europe (2000) J Muller-Nordhorn, et al. Eur Heart J 2008;29:Epub online

Age-standardized mortality rates (45–74 years) from all-cause mortality in Europe (2000) J Muller-Nordhorn, et al. Eur Heart J 2008;29:Epub online